세계의 동물용 생물학적 제제 시장 : 제품 유형별, 질환 유형별, 용도별, 유통 채널별, 지역별 - 기회 및 예측(2018-2032년)

Global veterinary biologics market is projected to witness a CAGR of 5.92% during the forecast period 2025-2032, growing from USD 17.13 billion in 2024 to USD 27.14 billion in 2032. The global veterinary biologics market demand is projected to rise as veterinary biologics serve as biological products that provide disease prevention or treatment and diagnostic capabilities for animals. The products, which consist of vaccines, bacterins, and diagnostic test kits, derive their components from living organisms. Also, the need for these products is rising consistently as these products function as essential tools that protect animal health while stopping diseases from spreading.

The global veterinary biologics market plays a crucial role in animal healthcare by distributing biological products, including include vaccines, antisera, and blood products used to protect animals from diseases. The market continues to expand significantly because of growing animal health knowledge and increasing cases of zoonotic diseases alongside expanding worldwide populations of livestock and pets. Technological progress in the field of biological development has produced enhanced biologics that drive the market's ongoing growth. Government programs for animal health and increasing investments from important industry players, and rising focus on food safety and public health serve as major factors driving the demand for veterinary biological. The increasing number of pets being adopted, particularly in developed countries, has led to greater consumption of biologics designed for companion animals. The market divides its analysis into product categories, animal categories, application segments, and regional divisions, with vaccines maintaining the largest portion since they serve as essential preventive measures against diseases. The market leaders include North America and Europe since these regions possess developed healthcare systems and supportive regulations, together with high numbers of pet owners. The market in the Asia-Pacific will experience the highest growth rate due to expanding livestock operations and increasing awareness and economic progress in developing nations.

At the same time, for the development of veterinary biologics, companies are forming partnerships to improve animal health. For instance, in August 2024, Akston Biosciences Corporation and Purdue University announced a strategic partnership to focus on co-developing an anti-cPD-L1 monoclonal antibody (mAb) immunotherapy to treat cancer in dogs.

Rising Prevalence of Zoonotic Diseases Increased Market Demand

The rising prevalence of zoonotic disease caused a major increase in the demand for veterinary biologics. The increasing prevalence of diseases such as COVID-19, together with avian influenza and rabies, requires immediate control measures to prevent their transmission from animals to humans. Public health protection through disease prevention in animals has become clear to both government agencies and healthcare providers, as well as livestock owners. Veterinary biologics experience significant market interest because vaccines, together with diagnostics and therapeutics, function as essential tools for outbreak response and current infection control. The expanding implementation of biosecurity measures and vaccination approaches generates growing requirements for veterinary biologics. The rising number of pet owners and livestock farmers has generated increased requirements for dependable biological products that support animal health and productivity. The increasing threat from zoonotic diseases has caused major expansion in the veterinary biologics market because these products serve essential functions for disease prevention worldwide.

For instance, in March 2024, a Spanish National Research Council announced collaboration with Zendal group launched Neoleish, the world's first DNA vaccine against canine leishmaniasis a serious zoonosis that can also be transmitted from animals to humans.

Advancements in Biotechnology Enhance Veterinary Biologics Market Demand

Developments in biotechnology alongside genetic engineering enable significant advancements in veterinary biologics development. The recent progress in recombinant vaccines and monoclonal antibodies alongside DNA-based immunizations improves therapeutic outcomes and lowers potential side effects. The contemporary biologics function by specifically identifying pathogens to generate enhanced immune responses that maintain protection for longer periods in livestock and pet animals. Scientists utilize genetic engineering methods to develop multivalent vaccines that merge numerous disease defenses within a single shot to reduce vaccination complexity and minimize the number of doses needed. Animal handling during repeated procedures remains difficult and causes stress to both livestock and farm workers in large-scale farming operations. Biologics become more appealing to veterinary practitioners and farmers in emerging economies through these innovations because they provide cost-effective and simple-to-use solutions. Modern biologics enhance disease resistance while minimizing multiple intervention needs to produce better animal health alongside increased productivity and sustainable farming methods. Global veterinary biologics will benefit from innovative research in gene editing and synthetic biology, which will generate advanced solutions for the future.

Additionally, to develop innovative vaccines, biotech firms received approval from the drug department. For instance, in January 2023, Dalan Animal Health, Inc., a biotech firm focused on insect health, announced that the U.S. Department of Agriculture (USDA) had granted a conditional license for the immunization of honeybees against American Foulbrood disease caused by Paenibacillus larvae.

Vaccines Hold the Largest Global Veterinary Biologics Market Share

The veterinary biologics market consists of vaccines because they provide essential disease prevention and control for animals. The administration cost remains low while the effectiveness of these vaccines stands high to protect animals from diseases, including rabies, foot-and-mouth disease, and avian influenza. The rising knowledge among farmers, together with pet owners, regarding animal health maintenance and disease prevention, creates increasing market demand for veterinary vaccines. Modern vaccine technology developments through recombinant and DNA-based vaccines have enhanced both their safety and effectiveness, which drives their growing market acceptance. The vaccine segment experiences market growth because of government programs that fight zoonotic diseases, along with regulatory approval processes. The veterinary biologics market will maintain its top position through vaccines because livestock production worldwide grows steadily and requires efficient immunization solutions. The protective function of vaccines safeguards animal health and preserves food supply chains which further helps agricultural businesses avoid monetary losses, driving the global market demand.

For instance, in September 2024, Merck & Co., Inc., announced that it would expand its new USDA-approved NOBIVAC NXT vaccine platform to add a best-in-class solution to protect cats against feline leukemia virus, one of the most common infectious diseases in cats. The company expects the vaccine will be available at veterinary clinics and hospitals nationwide this fall.

North America Dominates the Veterinary Biologics Market Size

North America leads the veterinary biologics market through its superior healthcare system and extensive knowledge of animal health, and large-scale R&D funding. Regional regulations impose rigorous standards that ensure the safety and effectiveness of biologic products, thus making consumers feel secure. Major veterinary companies in the U.S. and Canada create new vaccines to fight animal diseases, including rabies, avian influenza, and foot-and-mouth disease. The expanding pet ownership trends and increasing veterinary service requirements support ongoing market development. The veterinary biologics market expands through government-backed animal health programs, together with disease control initiatives. The distribution networks in North America, together with established veterinary clinics, allow biologic products to reach a broad customer base. North America leads the global veterinary biologics market because of its technological progress, together with extensive pet ownership and government initiatives for animal health.

For instance, in July 2023, Invetx, Inc. announced the completed development of their species-specific, half-life extension technology application for dogs and cats, which can enhance the extended duration of activity for the company's veterinary monoclonal antibodies. This novel technology allows the company to optimize evidence-based antibody drug treatment options for a precious animal's chronic, serious diseases. Invetx has been issued four patents in the U.S. relating to their half-life extension technology, and has multiple patents pending in the U.S., Europe, and other jurisdictions.

Impact of U.S. Tariffs on Global Veterinary Biologics Market

The veterinary biologics market experiences substantial effects from U.S. tariffs through changes to import expenses, pricing structures, and market competitiveness. When foreign biologics face elevated tariffs on their imported vaccines and diagnostics, and other biological products become more expensive which may drive up prices for veterinary practices and their customers. Domestic manufacturers receive encouragement to increase their production capabilities through this situation, yet restricted domestic capacity might reduce product diversity and innovation development. Tariffs create obstacles for international trade, which result in delayed availability of advanced biologics and supply chain disruptions. The implementation of tariffs by trading partners happens as a defensive reaction to these measures, thus generating additional market instability. The veterinary biologics market faces tariff-induced alterations in pricing levels and supply availability alongside changes to innovation patterns, which impact both animal health management and the broader agricultural industry. The protection of domestic industries versus affordable veterinary biologics access stands as a primary concern for all involved stakeholders.

Key Players Landscape and Outlook

Major players in the veterinary biologics market are a highly competitive scenario. These companies continually attempt to expand the market and improve their competitive position. They want to be seen as developed markets that want to introduce new products that meet people's needs through research and development. Key players in the veterinary biologics market pursue acquisitions and mergers as a strategy to expand their product portfolios. The veterinary biologics market will experience fast growth because several factors drive its expansion, including rising animal populations, growing animal protein demand and increasing awareness about animal health. The veterinary biologics market operates in a highly competitive environment because the main industry players strive to improve their market position.

In May 2023, Zoetis Inc. announced the approval of Librela (bedinvetmab injection) from the U.S. Food and Drug Administration (FDA) to control pain associated with osteoarthritis (OA) in dogs.

In October 2024, Elanco Animal Health Incorporated received a grant from the U.S. Food and Drug Administration (FDA) for Credelio Quattro to make the most expansive canine oral parasiticide available in the market because it protects against six types of parasites.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Veterinary Biologics Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product
    • 5.2.1.1. Vaccines
    • 5.2.1.2. Diagnostic Kits
    • 5.2.1.3. Immunomodulators
    • 5.2.1.4. Antiserums and Antibodies
    • 5.2.1.5. Others
  • 5.2.2. By Disease Type
    • 5.2.2.1. Bluetongue
    • 5.2.2.2. Foot and Mouth Disease
    • 5.2.2.3. Brucellosis and Tuberculosis
    • 5.2.2.4. Others
  • 5.2.3. By Application
    • 5.2.3.1. Production Animal
    • 5.2.3.2. Companion Animal
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Veterinary Hospitals
    • 5.2.4.2. Veterinary Clinics
    • 5.2.4.3. Retail Pharmacies
  • 5.2.5. By Region
    • 5.2.5.1. North America
    • 5.2.5.2. Europe
    • 5.2.5.3. Asia-Pacific
    • 5.2.5.4. South America
    • 5.2.5.5. Middle East and Africa
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product
  • 5.3.2. By Disease Type
  • 5.3.3. By Application
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. North America Veterinary Biologics Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Product
    • 6.2.1.1. Vaccines
    • 6.2.1.2. Diagnostic Kits
    • 6.2.1.3. Immunomodulators
    • 6.2.1.4. Antiserums and Antibodies
    • 6.2.1.5. Others
  • 6.2.2. By Disease Type
    • 6.2.2.1. Bluetongue
    • 6.2.2.2. Foot and Mouth Disease
    • 6.2.2.3. Brucellosis and Tuberculosis
    • 6.2.2.4. Others
  • 6.2.3. By Application
    • 6.2.3.1. Production Animal
    • 6.2.3.2. Companion Animal
  • 6.2.4. By Distribution Channel
    • 6.2.4.1. Veterinary Hospitals
    • 6.2.4.2. Veterinary Clinics
    • 6.2.4.3. Retail Pharmacies
  • 6.2.5. By Country Share
    • 6.2.5.1. United States
    • 6.2.5.2. Canada
    • 6.2.5.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Veterinary Biologics Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Product
        • 6.3.1.2.1.1. Vaccines
        • 6.3.1.2.1.2. Diagnostic Kits
        • 6.3.1.2.1.3. Immunomodulators
        • 6.3.1.2.1.4. Antiserums and Antibodies
        • 6.3.1.2.1.5. Others
      • 6.3.1.2.2. By Disease Type
        • 6.3.1.2.2.1. Bluetongue
        • 6.3.1.2.2.2. Foot and Mouth Disease
        • 6.3.1.2.2.3. Brucellosis and Tuberculosis
        • 6.3.1.2.2.4. Others
      • 6.3.1.2.3. By Application
        • 6.3.1.2.3.1. Production Animal
        • 6.3.1.2.3.2. Companion Animal
      • 6.3.1.2.4. By Distribution Channel
        • 6.3.1.2.4.1. Veterinary Hospitals
        • 6.3.1.2.4.2. Veterinary Clinics
        • 6.3.1.2.4.3. Retail Pharmacies
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Veterinary Biologics Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Veterinary Biologics Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Veterinary Biologics Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Veterinary Biologics Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Clinical Trials

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Bayer AG
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Eli Lilly & Company
  • 20.3.3. Evonik Industries AG
  • 20.3.4. Zoetis Inc.
  • 20.3.5. Merck & Co., Inc.
  • 20.3.6. Boehringer Ingelheim International GmbH
  • 20.3.7. Elanco Animal Health Incorporated
  • 20.3.8. IDEXX Laboratories Inc.
  • 20.3.9. Virbac S.A.
  • 20.3.10. Phibro Animal Health Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer